|
Press Releases |
|
|
|
Tuesday, March 15, 2022 |
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
Friday, March 11, 2022 |
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 9, 2022 |
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 7, 2022 |
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製のチロシンキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体「キイトルーダ(R)」(一般名:ペムブロリズマブ)との併用療法による治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得したことをお知らせします。 more info >> |
|
Friday, March 4, 2022 |
|
エーザイとバイオジェン、「レカネマブ」について日本での早期承認取得をめざし、医薬品事前評価相談制度に基づく申請データの提出を開始 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク (Nasdaq: BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)は、このたび、エーザイが、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブ(開発品コード:BAN2401)について、日本において医薬品事前評価相談制度に基づき、独立行政法人医薬品医療機器総合機構(PMDA)に申請データの提出を開始したことをお知らせします。 more info >> |
|
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab |
Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has initiated a submission to the Pharmaceuticals and Medical Devices Agency (PMDA) of application data under the prior assessment consultation system in Japan for the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (BAN2401). more info >> |
|
Friday, February 25, 2022 |
|
Eisai: LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Approved in Japan for Radically Unresectable or Metastatic Renal Cell Carcinoma |
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, plus KEYTRUDA. more info >> |
|
Friday, February 4, 2022 |
|
エーザイ、人事異動を発表 |
エーザイはこのたび、人事異動(2022年2月3日付 執行役人事異動)を以下のとおり発表しました。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Valuufy、千本倖生博士を取締役会長に任命、サステナビリティ評価に新時代到来を示唆
Oct 23, 2024 14:00: JST
|
|
|
Valuufy appoints Dr Sachio Semmoto to Chairman of the Board, Signaling a New Era in Sustainability Assessment
Oct 23, 2024 13:00: JST
|
|
|
World AI Show - Mumbai edition is set to Host AI experts and enthusiasts in Pivotal Talks on India's AI Revolution
Oct 23, 2024 12:43 HKT/SGT
|
|
|
Valuufy appoints Dr Sachio Semmoto as Chairman of the Board, Signaling a New Era in Sustainability Assessment
Oct 23, 2024 13:00 JST
|
|
|
TransNusa Signs Agreement with Three Renowned Medical Centres in Malaysia
Oct 23, 2024 11:00 HKT/SGT
|
|
|
BlackBerry Partners with ISC2 to Advance Cybersecurity Skills in Malaysia
Oct 23, 2024 10:00: JST
|
|
|
Fujitsu to offer AI agents that can both collaborate and engage in high-level tasks autonomously
Oct 23, 2024 10:55 JST
|
|
|
BlackBerry Partners with ISC2 to Advance Cybersecurity Skills in Malaysia
Oct 23, 2024 09:00 HKT/SGT
|
|
|
T.MAN Pharmaceutical PCL (SET: TMAN) Showcases Leadership in Health Innovation, Aiming for Sustainable Growth Following Listing on SET
Oct 23, 2024 09:00 HKT/SGT
|
|
|
GJK Facility Services Hosts Educational Session With Dr. Chantel Thornton During Breast Cancer Awareness Week
Oct 23, 2024 08:00: JST
|
|
|
Altezza Travel Wins Two Nominations at 2024 World Travel Awards
Oct 23, 2024 07:00 HKT/SGT
|
|
|
GJK Facility Services Hosts Educational Session With Dr. Chantel Thornton During Breast Cancer Awareness Week
Oct 23, 2024 07:00 HKT/SGT
|
|
|
ONERHT Foundation Celebrates 9th Charity Golf and Gala Dinner Event, Raising Over S$430,000 to Support 9 Charitable Organisations
Oct 22, 2024 23:00 HKT/SGT
|
|
|
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Oct 22, 2024 22:20 JST
|
|
|
Li Ning Partners with HongShan to Establish a Joint Venture
Oct 22, 2024 20:39 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|